New Report Details How U.S. Can Maintain Biotech Competitiveness

Why It Matters

A weakened early‑stage pipeline threatens U.S. leadership in drug innovation and could shift critical treatments to foreign developers, impacting patient access and economic growth.

Key Takeaways

• U.S. pipeline share dropped to 36% in 2025, near China.
• Phase 1 trial numbers are declining, raising development costs.
• Report urges modernizing IND requirements for faster human testing.
• Dedicated Phase 1 site network proposed to streamline early trials.
• Reducing litigation risk aims to attract more sponsors to U.S. trials.

Pulse Analysis

The United States has long been the engine of global drug discovery, but recent data signal a narrowing advantage. The Reagan‑Udall Foundation’s new report highlights a slide in pipeline share—from 47% in 2013 to just 36% in 2025—bringing the U.S. almost level with China. Coupled with a noticeable dip in Phase 1 trial initiations, the trend threatens the nation’s ability to translate scientific breakthroughs into marketable medicines, potentially ceding market leadership and patient access to overseas competitors.

To reverse the drift, the report offers a suite of reforms focused on the earliest stages of development. Streamlining Investigational New Drug (IND) submissions and clarifying data expectations would cut administrative lag, while AI‑driven trial designs and earlier patient input promise more efficient Phase 1 studies. Enhanced FDA‑sponsor communication and a dedicated network of Phase 1 sites aim to reduce uncertainty and logistical bottlenecks. Perhaps most critical is the call to mitigate litigation risk for trial sites, a move intended to encourage more sponsors to run early trials domestically without compromising safety standards.

If policymakers and industry leaders act on these recommendations, the U.S. could restore its pipeline momentum and safeguard a pipeline of high‑value therapeutics. Investors would likely see renewed confidence in biotech ventures, while patients benefit from faster access to innovative treatments. Conversely, inertia could deepen reliance on foreign pipelines, eroding both economic and health security. The report thus serves as a strategic roadmap for preserving America’s biotech competitiveness in an increasingly contested global arena.